Randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance reports evaluating GI adverse effects of GLP-1based therapies were included
Reviewed by Paul Holmes Paul Holmes Director of Science and Innovation at Naturecan Testing for large pharmaceutical & tobacco companies, Paul has built a wealth of scientific and regulatory knowledge, working on regulatory submissions to bodies such as the FDA and the MHRA
These results are genuinely impressive
The study found increased risk in both patients with type 2 diabetes and patients using semaglutide for overweight or obesity, but the authors noted that the study was observational and could not prove that semaglutide directly caused NAION
I tell my patients to shoot for 1.2 to 1.6 grams per kilogram while theyre losing weight on a GLP-1. Dr
Instead, wait until the following Saturday (nine-day gap), then continue on Saturdays